Wednesday, September 19, 2018
Presstek visiting Kuopio: Finvector Introduction 13.9.2018
FinVector is a world leader in the research and development of Viral-Based Gene Therapy products, with state-of-the-art facilities and a highly experienced scientific team working in the gene therapy market.
They deliver a tailored service to meet and exceed our clients’ needs, and use our scientific expertise and industry knowledge to help clients take viral-based products from the pre-clinical phase, through clinical trials and to the market.
Source: Presstek visit 13.9.2018 and http://www.finvector.com/